{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+alirocumab%29", "query": { "intervention": "Placebo (for alirocumab)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+alirocumab%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T15:02:48.575Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05469347", "title": "Alirocumab in Patients with Sepsis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sepsis" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonathan Sevransky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 50, "start_date": "2023-01-04", "completion_date": "2025-02-23", "has_results": false, "last_update_posted_date": "2025-03-24", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05469347" }, { "nct_id": "NCT03507374", "title": "PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stroke", "Intracranial Atherosclerosis", "Intraplaque Hemorrhage" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-10-30", "completion_date": "2020-04-17", "has_results": false, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507374" }, { "nct_id": "NCT02585778", "title": "Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Lipid-Modifying Therapy (LMT)", "type": "DRUG" }, { "name": "Antihyperglycemic Drug", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 517, "start_date": "2015-10-23", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 29, "location_summary": "Encino, California • Fresno, California • Oakland, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Loveland", "state": "Colorado" }, { "city": "Atlantis", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02585778" }, { "nct_id": "NCT01959971", "title": "Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2013-12", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2017-05-02", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01959971" }, { "nct_id": "NCT03510884", "title": "An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab SAR236553 (REGN727)", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Simvastatin", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" }, { "name": "Lovastatin", "type": "DRUG" }, { "name": "Fluvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Cholestyramine", "type": "DRUG" }, { "name": "Nicotinic acid", "type": "DRUG" }, { "name": "Fenofibrate", "type": "DRUG" }, { "name": "Omega-3 fatty acids", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 153, "start_date": "2018-05-31", "completion_date": "2022-08-05", "has_results": true, "last_update_posted_date": "2023-05-06", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 5, "location_summary": "Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03510884" }, { "nct_id": "NCT01663402", "title": "ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerotic Cardiovascular Disease" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "LMT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 18924, "start_date": "2012-10", "completion_date": "2018-01-23", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 273, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 218 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663402" }, { "nct_id": "NCT01623115", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 486, "start_date": "2012-07", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2016-02-08", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 26, "location_summary": "Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01623115" }, { "nct_id": "NCT01617655", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo (for alirocumab)", "type": "DRUG" }, { "name": "Lipid Modifying Therapy (LMT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2012-06", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 14, "location_summary": "Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more", "locations": [ { "city": "Bell Gardens", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01617655" }, { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT03175367", "title": "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Evinacumab", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" }, { "name": "Background Lipid Modifying Therapy (LMT)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 272, "start_date": "2017-11-10", "completion_date": "2020-12-14", "has_results": true, "last_update_posted_date": "2023-02-10", "last_synced_at": "2026-10-01T15:02:48.575Z", "location_count": 23, "location_summary": "Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175367" } ] }